Fibrin Sealant Patents: Leaders, Trends & White Space 2026
Fibrin sealant and biological glue patents: who holds the ground and where it is still open
Concentrated at the top. The five leading assignees together hold 24.1% of all 3,837 records in scope, and the leading ten hold 33.3% — a long tail of smaller filers fills the rest. Filings peaked at 193 records in 2017. The comparable full-year window shows a 45% drop from 86 records in 2021 to 47 in 2024; 2025 and 2026 figures are still filling in as publications catch up with filing dates.
- 1OMRIX BIOPHARMACEUTICALS LTD7.2%
- 2BAXTER INT INC6.8%
- 3BAXTER HEALTHCARE SA3.9%
- 4ANGIOTECH INT AG (CH)3.2%
- 5NOVARTIS AG2.9%
See the full fibrin sealants and biological glues analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about fibrin sealant patents
Who holds the most fibrin sealant patents?
The dataset ranks 100 assignees by patent family count, and the leading assignee holds 276 records, well ahead of the fifth-ranked entity at 113 and the tenth at 55. The top five combined account for 24.1% of all 3,837 records in scope, and the top ten for 33.3%. Beyond that leading group, ownership spreads across a long tail of smaller filers, so no single company controls the majority of the field.
Is fibrin sealant patent activity growing or declining?
Filing peaked at 193 records in 2017 and has since cooled, with the last comparable full-year window showing a 45% drop from 86 records in 2021 to 47 in 2024. Because publication typically lags filing by around 18 months, the 2025 and 2026 figures are still incomplete and should not be read as evidence of further decline. The pattern is consistent with a formulation space that matured after an earlier wave of core patenting rather than one being abandoned.
What technology areas do fibrin sealant patents cover?
The two largest IPC subclasses are A61L, sterilising and disinfecting, covering 51.7% of the 3,837 records, and A61K, medicinal preparations, covering 48.7%. Implants and prostheses (A61F), therapeutic activity (A61P), diagnosis and surgery (A61B), and genetic engineering (C12N) each cover meaningfully smaller shares. Because a single record can carry multiple IPC classes, these percentages add up to more than 100% and should be read as overlapping coverage, not a breakdown of distinct segments.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Fibrin Sealants and Biological Glues covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.